Loading Events

« All Events

  • This event has passed.

18th Annual Pharmacovigilance 2019

February 27 - February 28

18th Annual Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organization’s compliance with pharmacovigilance requirements. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.




  • JACKIE ROBERTS, Executive Director Regulatory, Pharmacovigilance and Medical / QPPV, Accord Healthcare
  • JABEEN AHMAD, Regional PV Director, EEMEA, Abbvie
  • SUSAN WELSH, Chief Safety Officer, CSL Behring (USA)
  • RICARDA TIEMEYER, Head of Drug Safety & PoC Medical Information, Roche
  • PAOLO VOLTOLINA, Associate Director Regulatory Affairs, CSL Behring
  • MIROSLAVA NOVAKOVA, Medical Advisor, Sanofi Pasteur (Slovak Republic)
  • YUUNG YUUNG YAP, Senior International Regulatory Counsel, EU and International Regulatory Law, Pfizer
  • DAVID JEFFERYS, VP Regulatory, Eisai
  • TANJA PETERS, Global Head of PV Intelligence, Deputy EU QPPV, Boehringer Ingelheim
  • JOHN SOLOMON, Head of Pharmacovigilance – UK & Ireland, Sanofi
  • VINEET KACKER, Co-Founder, Global Technical Director and QPPV, APCER Lifesciences
  • MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Johnson & Johnson
  • PHILIP OLUWOLE, Associate Principal Surveillance Specialist, AstraZeneca
  • EMANUEL LOHRMANN, Lead Safety Physician, Boehringer Ingelheim
  • STEINAR MADSEN, Medical Director, Norweigen Medicines Agency
  • PHILLIP EICHORN, Senior Director (Worldwide Safety and Regulatory), Pfizer
  • PAUL WANG, Director, Safety Science, Kite Pharma (USA)
  • DORIS STENVER, Chief Medical Officer, Member of the Pharmacovigilance Risk Assessment Committee (PRAC), Danish Medicines Agency
  • ALEJANDRA PADOVANI, Safety Scientist, Roche
  • HEINZ WEIDENTHALER, Director Pharmacovigilance, QPPV, Bavarian Nordic
  • MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates (India)
  • MIRCEA CIUCA, Global Head Medical & Clinical Drug Safety, Vifor Pharma
  • FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead – Compliance and Regulatory Affairs, Novartis
  • ALINA TUDOR, Associate Director, Senior PV Physician/Deputy EUQPPV, Norgine
  • RAJ BHOGAL, Safety & International Director, Regulatory Inspections, R&D QA&C, Shire Pharmaceuticals

Plus many more


  • Brexit Implications for the UK Pharmaceutical (pharmacovigilance) Industry
  • What would ‘no deal’ mean for medicine?
  • New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
  • Quality, Safety and Signal Detection – Future of 2020
  • PV Audit & Inspections – Knowing what is to be done
  • Drug safety work in the pre-clinical/clinical transition and early clinical development phase
  • Pharmacovigilance in 2020 – future horizons and efficiencies
  • Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
  • Possible effects of Brexit on Pharmacovigilance
  • Benefit/Risk ratio: the common denominator
  • Market analysis – What is our current stand? – Moving towards the new successful PV era
  • PV – Risk Management and Planning
  • Risk management in the lifecycle of a drug
  • Examining developments in GVP measures and status of the new Module VI
  • Improving in signal management and their implications
  • Latest updates and hot topics relating to the role of the QPPV
  • Challenges and Opportunities to optimize the overall PV ecosystem for maximum benefit
  • Quality, Safety and Signal Detection – Future of 2020
  • Medical devices – Increasing safety perspective
  • Case studies from various countries on the PV frameworks around the world
  • Good Clinical Practices and Good Pharmacovigilance practices
  • Proper communication – Sponsor – Site – CRO & Patients
  • Patient centric approach to help improve patient safety
  • Outsourcing activities – How to set it right?
  • How to involve patients better to develop drugs
  • The developing regulatory framework in advanced and developing markets – EU, USA & ROW
  • Accelerating new medicine introduction in developing world & overcoming challenges
  • Be part of a major networking opportunity


CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing.


February 27
February 28
Event Category:


Virtue Insight


Pestana Chelsea Bridge Hotel
354 Queenstown Rd
London, SW11 8AE United Kingdom
+ Google Map
+44 20 7062 8000

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.